Introduction:
Since time immemorial, human Echinococcosis has represented a serious disease burden of global concern (1,2). It is a parasitic disease caused by the infection of larval stages of tapeworms belong to genus Echinococcus through the ingestion of food or water contaminated with their eggs, or by a direct contact with the animal hosts. The development of the larvae of Echinococcus Granulosus in humans (as accidental intermediate hosts) leads to Cystic Echinococcosis (CE) (Hydatidosis) (1,2,3). It is a hyperendemic disease in different regions of the world, significantly in rural areas (1,4). The most frequently involved organs by hydatidosis are liver (more than 65% of cases) and lungs (both comprise at least 90% of cases) (1,5). Cardiac hydatid disease is rare (0.5-2% of all locations), and this may be due to the filtration of the embryos through the liver and lungs, and to the fact that cardiac rhythmic contractions prevent the cysts to implant within the cardiac wall.(3,6). Clinical presentation of cardiac hydatid cysts is quite variable and depends on the age, size, location, and integrity of the cyst. In the majority of cases, patients are asymptomatic. Most common reported symptoms are dyspnea, chest pain, palpitations, and cough (3,8,9). On the other hand, it may present with life threatening events such as anaphylactic shock, pulmonary embolism, acute coronary syndrome, or malignant arrhythmias due to subendocardial rupture which leads to the release of cyst contents into the blood stream. (2,3,7). In endemic geographic areas, the most important issue regarding diagnosis is clinical suspicion. Transthoracic echocardiography (TTE) is the main diagnostic tool for cardiac hydatid disease. Computed tomography(CT) and magnetic resonance imaging (MRI) may provide additional diagnostic information (2,3,7) . Surgery is the treatment of choice in all cases to achieve higher survival rates with lower recurrence (1-10).